Suche Medizinische Publikationen
Suche Abbildungen und Grafiken
Medizinprodukte - Labortechnik
Antidotarium (Stand 2012)
Phytokodex (Stand 2012)
Endoskopie in Österreich (Stand 2010)
Kardiologie in Österreich (Stand 2006)
Osteologie in Österreich (Stand 2016)
Fachbücher
Patientenliteratur
Geisthövel F, Wacker A, Brabant G, Botsch F, Maechtel A, Wetzka B, Ochsner A Novel Systematics of Nomenclature and Classification of Female Functional Androgenization (Including Polycystic Ovary Syndrome and Non-Classic Congenital Adrenal Hyperplasia) Journal für Reproduktionsmedizin und Endokrinologie - Journal of Reproductive Medicine and Endocrinology 2010; 7 (1): 6-26 Volltext (PDF) Summary Übersicht
| ||||||
Abbildung 3: Box plots Box plots of serum lipids, the major secondary (facultative) variable, in all groups of patients with functional androgenization. For legend see Figure 2. Dotted lines represent the respective cut-off values: triglycerides (150 mg/dL), high density lipoprotein (HDL)-cholesterol (50 mg/dL). Statistically significant differences are: Triglycerids: FCA vs. III, IV 0.0021, 0.0301 FAS I vs. III, IV < 0.0001, 0.0161 FAS III vs. II, C 0.0014, 0.0003 HDL : FAS I vs.II–IV 0.0306, < 0.0001, 0.0003 FAS III vs. FCA, C 0.0173, 0.0001 FAS IV vs. C 0.0030 |
Abbildung 3: Box plots
Box plots of serum lipids, the major secondary (facultative) variable, in all groups of patients with functional androgenization. For legend see Figure 2. Dotted lines represent the respective cut-off values: triglycerides (150 mg/dL), high density lipoprotein (HDL)-cholesterol (50 mg/dL). Statistically significant differences are: Triglycerids: FCA vs. III, IV 0.0021, 0.0301 FAS I vs. III, IV < 0.0001, 0.0161 FAS III vs. II, C 0.0014, 0.0003 HDL : FAS I vs.II–IV 0.0306, < 0.0001, 0.0003 FAS III vs. FCA, C 0.0173, 0.0001 FAS IV vs. C 0.0030 |